Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Phase 1 Completed 63 enrolled Sanofi

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study was designed to evaluate the safety, tolerability, and immunogenicity of three doses of an investigational pneumococcal vaccine in healthy adult volunteers. Primary Objective: * To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.

Timeline

Start: 2007-02
Primary completion: 2007-08
Completion: 2007-08

Publications

Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012 Dec 14;30(52):7455-60. doi: 10.1016/j.vaccine.2012.10.080. Epub 2012 Nov 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PhtD vaccine candidate	Protein / enzyme biologic	6 ug	Intramuscular
Subject	PhtD vaccine candidate	Protein / enzyme biologic	25 ug	Intramuscular
Subject	PhtD vaccine candidate	Protein / enzyme biologic	100 ug	Intramuscular

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Summary

Timeline

Publications

Drugs

Indications